| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 25.01.
| Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds | | 24 | Business Wire |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company developing and commercializing best in class
oncology and CNS therapeutics, today...
Mehr lesen zu:
Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds | |
| 18.01.
| Rexahn Pharma Gets Approval For First Human Trial Of RX-3117 | | 55 | AFX News |
| PETAH TIKVA (dpa-AFX) - Rexahn Pharmaceuticals, Inc. (RNN) Wednesday said it
has secured approval in Hungary to initiate an exploratory first-in-human Phase
I clinical trial of RX-3117,...
Mehr lesen zu:
Rexahn Pharma Gets Approval For First Human Trial Of RX-3117 | |
| 18.01.
| Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors | | 23 | Business Wire |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company developing and commercializing oncology and CNS
therapeutics, today announced that...
Mehr lesen zu:
Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors | |
| 17.01.
| Rexahn Pharmaceuticals Provides Key Goals for 2012 | | 23 | Business Wire |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing oncology and CNS therapeutics,
today provided guidance on its key...
Mehr lesen zu:
Rexahn Pharmaceuticals Provides Key Goals for 2012 | |
| 09.11.
| Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests / The Bedford Report Provides Equity Research on Rexahn Pharmaceuticals & Elite Pharmaceuticals | | 28 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 11/09/11 -- Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation and shockingly...
Mehr lesen zu:
Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests / The Bedford Report Provides Equity Research on Rexahn Pharmaceuticals & Elite Pharmaceuticals | |
| 04.11.
| Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin® as Treatment for Major Depressive Disorder | | 37 | Business Wire |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced...
Mehr lesen zu:
Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin® as Treatment for Major Depressive Disorder | |
| 12.10.
| Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds | | 24 | Business Wire |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced...
Mehr lesen zu:
Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds | |
| 03.10.
| Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin® | | 33 | Business Wire |
| Study sheds light on Serdaxin as an enhancer of dopamine and serotonin
release (SERDA);
Novel mechanism may be able to address both negative mood and loss...
Mehr lesen zu:
Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin® | |
| 28.09.
| Rexahn Pharmaceuticals Completes Patient Enrollment for Archexin Phase II Clinical Trial in Metastatic Pancreatic Cancer | | 32 | Business Wire |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced...
Mehr lesen zu:
Rexahn Pharmaceuticals Completes Patient Enrollment for Archexin Phase II Clinical Trial in Metastatic Pancreatic Cancer | |
| 08.09.
| Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 13th Annual Healthcare Conference | | 30 | Business Wire |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company developing and commercializing potential best in
class oncology and CNS therapeutics...
Mehr lesen zu:
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 13th Annual Healthcare Conference | |
| 06.09.
| Rexahn Pharmaceuticals Announces US Patent Issued for CNS-based Treatment of Sexual Dysfunction | | 17 | Business Wire |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced...
Mehr lesen zu:
Rexahn Pharmaceuticals Announces US Patent Issued for CNS-based Treatment of Sexual Dysfunction | |
